TABLE 2.
Clinical baseline characteristics of the training and testing sets.
| Characteristics | Training set (n = 899) | Testing set (n = 386) | χ 2 | p |
|---|---|---|---|---|
| Liver cancer [n (%)] | 190 (21.13) | 75 (19.43) | 0.042 | 0.489 |
| Male [n (%)] | 642 (71.41) | 265 (68.83) | 0.056 | 0.352 |
| Age (mean ± SD) | 52 ± 13.00 | 52 ± 11.25 | 0.889 | 0.011 |
| Hb < 136.5 g/L [n (%)] | 390 (43.38) | 169 (43.78) | 0.018 | 0.894 |
| NP% ≥ 69.85% [n (%)] | 266 (29.59) | 115 (29.79) | 0.005 | 0.941 |
| TP ≥ 72.67 g/L [n (%)] | 274 (30.48) | 114 (29.53) | 0.114 | 0.735 |
| GGT ≥ 68.55 U/L [n (%)] | 349 (38.82) | 140 (36.27) | 0.746 | 0.388 |
| AFU ≥ 20.41 U/L [n (%)] | 562 (62.51) | 241 (62.44) | 0.001 | 0.979 |
| AAR ≥ 1.33 [n (%)] | 349 (38.82) | 159 (41.19) | 0.635 | 0.426 |
| AFP ≥ 380.26 ng/mL [n (%)] | 118 (13.13) | 40 (10.36) | 1.912 | 0.167 |
Abbreviations: AAR, aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio; AFP, alpha‐fetoprotein; AFU, alglucosidase alfa; GGT, glutamyl transpeptidase; Hb, hemoglobin; NP, neutrophil percentage; TP, total protein.